Anna Shikhman

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

Benoît Trottier, Sharon Walmsley, Jacques Reynes et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 81 citations

Pharmacy, Pharmacotherapy, Infectious Disease Pharmacotherapy +14

1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS

Edward Gane, Paul J. Pockros, Stefan Zeuzem et al. · Journal of Hepatology · 2012 · 55 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive <scp>HCV</scp> genotype 1 patients: <scp>INFORM</scp> ‐ <scp>SVR</scp> study

Edward Gane, Paul J. Pockros, Stefan Zeuzem et al. · Liver International · 2014 · 25 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients

David H. Wright, Allen E. Rodriguez, Eliot Godofsky et al. · HIV Clinical Trials · 2008 · 12 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17